Mr. Rene Goehrum reports

BIOSYENT PHARMA SIGNS EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENT FOR A NEW GASTROINTESTINAL HEALTH PRODUCT ALREADY APPROVED BY HEALTH CANADA-2014 LAUNCH PLANNED

BioSyent Inc.'s subsidiary, BioSyent Pharma Inc., has signed an exclusive canadian licence and distribution agreement with an existing European partner for a gastrointestinal health product that has already been approved by Health Canada.

This licence agreement is with the same partner that will be supplying the women's health product that is being prepared for launch in the second quarter of this year. The new product has been approved in several European countries and is being successfully marketed there.

"Prelaunch preparations have commenced and we are planning for a fourth quarter 2014 launch of this new gastrointestinal product," said Rene Goehrum, BioSyent chief executive officer. "It will be a good complement to both our existing promotion activities with health care practitioners and to our hospital products group. This product is also a direct complement to the women's health product which we will be launching in a couple of months.

"This new agreement brings the total number of products that BioSyent has licensed from European partners to five. One is approved and in the market (Cathejell), two more are already approved and will be launched this year, and two are in the process of review for approval by Health Canada. Along with FeraMAX 150 and FeraMAX powder, this brings our total product portfolio to seven products."

We seek Safe Harbor.